You are here: Home » PTI Stories » National » News
Business Standard

Glenmark Pharma launches generic version of asthma drug in Denmark

Press Trust of India  |  New Delhi 

Pharmaceuticals Ltd has launched a generic version of Seretide Accuhaler, used to treat asthma, in

The product was developed by Celon Pharma and has marketing and distribution rights for the product across 15 European countries.

"This is Glenmark's first inhaled respiratory product launch in is the first generic company to receive regulatory approval for substitution in for its generic of Seretide Accuhaler," said in a BSE filing.

Glenmark had entered into a strategic development and licensing agreement with to develop and market a generic version of GlaxoSmithKline's product - Fluticasone/Salmeterol dry powder inhaler in 15 European countries.

Fluticasone/Salmeterol dry powder inhaler is a for the treatment of and (COPD), it added.

Glenmark said it has already received National Marketing Authorizations for the product in Sweden, Finland, and

Quotng IQVIA data, said Fluticasone/Salmeterol dry powder Inhaler (DPI) had sales of USD 864 million in in the 12 month period ending September 2017.

Shares of were trading 0.25 per cent lower at Rs 505 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, May 16 2018. 10:25 IST